my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
19-06-2012: Trophos SA announced the appointment of Christine Placet as chief executive officer, effective immediately.
Christine was previously CFO of Trophos since 2004. Christine becomes CEO under a previously defined internal succession plan designed to provide continuity for Trophos. Trophos is financed to 2014.
Christine becomes CEO with a mandate to continue to bring the Trophos’ ongoing programs to a successful conclusion and to seek strategic partnerships for Trophos’ advance clinical development drug candidates.
Christine Placet has over 25 years' experience in a variety of areas of finance and business management. Prior to joining Trophos as CFO in 2004, she was CFO in a number of growing companies and start-ups in various industries, and worked as an auditor for eight years for Ernst & Young. She has a graduate diploma in financial accounting (DESCF) and a business school diploma from Sup de Co Marseille (DESCAF).
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Trophos SA announced the conclusion of the pan-European MitoTarget Project, the EU funded orphan disease project, with submission of the final report to the EC.The results obtained in this project included additional confirmation that mitochondrial dysfunction plays an important role in neu ... more
Trophos appoints Christine Placet as chief executive officer
Trophos SA announced the appointment of Christine Placet as chief executive officer, effective immediately.Christine was previously CFO of Trophos since 2004. Christine becomes CEO under a previously defined internal succession plan designed to provide continuity for Trophos. Trophos is fin ... more
Trophos announces results of phase III study of olesoxime in Amyotrophic Lateral Sclerosis
Trophos SA announced the results from the phase III study of Trophos’ lead compound, olesoxime, in 512 patients with ALS. Olesoxime did not demonstrate a significant increase in survival versus placebo in patients receiving riluzole (Rilutek(R)). A trend was seen on patients’ function as me ... more
Trophos is a clinical stage pharmaceutical company developing innovative therapeutics for indications with under-served needs in neurology and cardiology. more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
